Literature DB >> 21106845

Distinct roles for the NK cell-activating receptors in mediating interactions with dendritic cells and tumor cells.

Lu-En Wai1, Jordan A Garcia, Olivia M Martinez, Sheri M Krams.   

Abstract

NK cells are innate immune cells that are important in tumor immunity, but also have the ability to modulate the adaptive immune system through cytokine production or direct cell-cell interactions. This study investigates the interaction of NK cells with dendritic cells (DCs) and tumor cells, and the role of specific NK cell-activating receptors in this process. Primary rat NK cells and an NK cell line produced IFN-γ when cocultured with either DCs or the rat hepatoma cell line McA-RH7777 (McA). This NK cell activation by DCs and McA required cell-cell contact and was dependent on distinct NK-activating receptors. Silencing NK cell expression of NKp46 and NKp30 significantly diminished DC- and McA-mediated NK cell IFN-γ production, respectively. NK cells killed immature and mature DCs independently of NKp46, NKp30, and NKG2D; however, cytotoxicity against McA cells was dependent on NKp30 and NKG2D. Thus, we have shown in this study that NKp30 plays dual activating roles in NK-McA tumor interactions by mediating cytokine production and cytotoxicity. More importantly, NK cells are activated by both DCs and hepatoma cells to produce IFN-γ, but require distinct NK cell-activating receptors, NKp46 and NKp30, respectively. Our data suggest that therapeutics could be developed specifically to target NK-DC interactions without compromising NK tumor immunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106845      PMCID: PMC3433947          DOI: 10.4049/jimmunol.1002597

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

Review 1.  MHC class I molecules and KIRs in human history, health and survival.

Authors:  Peter Parham
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

2.  A transmembrane-anchored rat RAE-1-like transcript as a ligand for NKR-P2, the rat ortholog of human and mouse NKG2D.

Authors:  Balasubramanian Savithri; Ashok Khar
Journal:  Eur J Immunol       Date:  2006-01       Impact factor: 5.532

3.  Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity.

Authors:  Christopher E Andoniou; Serani L H van Dommelen; Valentina Voigt; Daniel M Andrews; Geraldine Brizard; Carine Asselin-Paturel; Thomas Delale; Katryn J Stacey; Giorgio Trinchieri; Mariapia A Degli-Esposti
Journal:  Nat Immunol       Date:  2005-09-04       Impact factor: 25.606

4.  NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor.

Authors:  Massimo Vitale; Mariella Della Chiesa; Simona Carlomagno; Daniela Pende; Maurizio Aricò; Lorenzo Moretta; Alessandro Moretta
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

5.  Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.

Authors:  Tal I Arnon; Hagit Achdout; Ofer Levi; Gal Markel; Nivin Saleh; Gil Katz; Roi Gazit; Tsufit Gonen-Gross; Jacob Hanna; Efrat Nahari; Angel Porgador; Alik Honigman; Bodo Plachter; Dror Mevorach; Dana G Wolf; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2005-04-10       Impact factor: 25.606

6.  Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.

Authors:  Masahisa Jinushi; Tetsuo Takehara; Tomohide Tatsumi; Naoki Hiramatsu; Ryotaro Sakamori; Shinjiro Yamaguchi; Norio Hayashi
Journal:  J Hepatol       Date:  2005-06-29       Impact factor: 25.083

7.  Evidence that the cellular ligand for the human NK cell activation receptor NKp30 is not a heparan sulfate glycosaminoglycan.

Authors:  Hilary S Warren; Allison L Jones; Craig Freeman; Jayaram Bettadapura; Christopher R Parish
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

8.  Identification of the rat NKG2D ligands, RAE1L and RRLT, and their role in allograft rejection.

Authors:  Ming Zhuo; Masato Fujiki; Mouer Wang; Karine Piard-Ruster; Lu-En Wai; Liang Wei; Olivia M Martinez; Sheri M Krams
Journal:  Eur J Immunol       Date:  2010-06       Impact factor: 5.532

9.  NKp30 (NCR3) is a pseudogene in 12 inbred and wild mouse strains, but an expressed gene in Mus caroli.

Authors:  Martine Hollyoake; R Duncan Campbell; Begoña Aguado
Journal:  Mol Biol Evol       Date:  2005-05-04       Impact factor: 16.240

10.  Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients.

Authors:  Valerie Chew; Charlene Tow; Marissa Teo; Hing Lok Wong; Jasmine Chan; Adam Gehring; Marie Loh; Alexandre Bolze; Richard Quek; Victor K M Lee; Kang Hoe Lee; Jean-Pierre Abastado; Han Chong Toh; Alessandra Nardin
Journal:  J Hepatol       Date:  2009-08-03       Impact factor: 25.083

View more
  12 in total

1.  Changes in natural killer cell subsets in pediatric liver transplant recipients.

Authors:  Betty Pham; Karine Piard-Ruster; Richard Silva; Amy Gallo; Carlos O Esquivel; Olivia M Martinez; Sheri M Krams
Journal:  Pediatr Transplant       Date:  2012-03

Review 2.  NK cells after transplantation: friend or foe.

Authors:  Uzi Hadad; Olivia Martinez; Sheri M Krams
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

3.  Clinically applicable magnetic-labeling of natural killer cells for MRI of transcatheter delivery to liver tumors: preclinical validation for clinical translation.

Authors:  Kangan Li; Andrew C Gordon; Linfeng Zheng; Weiguo Li; Yang Guo; Jing Sun; Guixiang Zhang; Guohong Han; Andrew C Larson; Zhuoli Zhang
Journal:  Nanomedicine (Lond)       Date:  2015       Impact factor: 5.307

Review 4.  NK cells: immune cross-talk and therapeutic implications.

Authors:  Anshu Malhotra; Anil Shanker
Journal:  Immunotherapy       Date:  2011-10       Impact factor: 4.196

5.  Hepatoma cell-derived leptin downregulates the immunosuppressive function of regulatory T-cells to enhance the anti-tumor activity of CD8+ T-cells.

Authors:  Renxiong Wei; Yaoren Hu; Feibo Dong; Xiaozhen Xu; Airong Hu; Guosheng Gao
Journal:  Immunol Cell Biol       Date:  2015-12-07       Impact factor: 5.126

Review 6.  Molecular targeting of liposomal nanoparticles to tumor microenvironment.

Authors:  Gang Zhao; B Leticia Rodriguez
Journal:  Int J Nanomedicine       Date:  2012-12-28

7.  An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.

Authors:  Yair Tal; Shlomo Yaakobi; Miryam Horovitz-Fried; Einav Safyon; Benyamin Rosental; Angel Porgador; Cyrille J Cohen
Journal:  Oncotarget       Date:  2014-11-15

8.  Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor.

Authors:  Vasyl Eisenberg; Katerina Shamalov; Shimrit Meir; Shiran Hoogi; Rhitajit Sarkar; Shirel Pinker; Gal Markel; Angel Porgador; Cyrille J Cohen
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561

9.  Molecular action of lenalidomide in lymphocytes and hematologic malignancies.

Authors:  Jessica M McDaniel; Javier Pinilla-Ibarz; P K Epling-Burnette
Journal:  Adv Hematol       Date:  2012-07-24

10.  NKp46 Clusters at the Immune Synapse and Regulates NK Cell Polarization.

Authors:  Uzi Hadad; Timothy J Thauland; Olivia M Martinez; Manish J Butte; Angel Porgador; Sheri M Krams
Journal:  Front Immunol       Date:  2015-09-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.